TogoTuberculosis profile
Population  2016 7.6 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.32 (0.21–0.44) 4.1 (2.8–5.8)
Mortality (HIV+TB only) 0.17 (0.12–0.22) 2.2 (1.6–2.9)
Incidence  (includes HIV+TB) 3.5 (2.8–4.2) 46 (37–56)
Incidence (HIV+TB only) 0.77 (0.5–1.1) 10 (6.5–14)
Incidence (MDR/RR-TB)** 0.11 (0.023–0.2) 1.5 (0.3–2.7)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.14 (0.11–0.17) 1.3 (1–1.5) 1.4 (1.1–1.7)
Males 0.16 (0.13–0.2) 1.9 (1.5–2.3) 2.1 (1.7–2.5)
Total 0.31 (0.24–0.37) 3.2 (2.6–3.8) 3.5 (2.8–4.2)
TB case notifications, 2016  
Total cases notified 2 849
Total new and relapse 2 755
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 99%
          - % pulmonary 86%
          - % bacteriologically confirmed among pulmonary 92%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 79% (65–97)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.14 (0.1–0.19)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 620 22%
          - on antiretroviral therapy 572 92%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  70
(12–130)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 5.4% (2.6–9.7)  
% notified tested for rifampicin resistance 5% 55% 236
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 11, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 10, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2015 86% 2 526
Previously treated cases registered in 2015 80% 145
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 100% 1
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
32% (29–35)
TB financing, 2017  
National TB budget (US$ millions) 2.6
Funding source: 12% domestic, 88% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data